ARCHIVES

GAO Backs DeVita On Why advances Aren’t Producing Mortality Reduction

This article is from The Cancer Letter archive.

Vol. 14 No. 06 | February 5, 1988

Download PDF Visit The Full Archive

Related Articles

Advisory Council To Be Named For Alternative Medicine Cuts

May 27, 1994

In Brief: Columbia’s Marks Reportedly Will Move To MSK; FDA Committee to Consider THC For Group C List

May 23, 1980

NCI Programs: Advisors Approve Recompetition of Phase II Contracts

July 9, 1999

Hoogstraten Resignation Sidetracks Kansas’ Move to Comprehensive Status, Threatens Core Grant

February 15, 1980

Von Eschenbach Says He Will Step Down as NCI Director; No Acting Director Has Been Named.

March 24, 2006

Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles With SEC Over Shorting Dendreon Stock

December 17, 2013